""For instance, if your triglyceride is 100 and your HDL is 50, your ratio is 2 to 1. That is very good. Ratios of two or under are very low risk. Ratios of 5 or higher are very high risk.
"It's hard to raise your HDL, but if you can get your triglycerides to drop, the ratio drops even if the HDL stays the same. Anything that lowers triglycerides is a good thing."
"One reason I recommend that people take bergamot extract is that it lowers triglycerides and changes LDL-B to LDL-A.
"If we’re trying to reduce heart disease, lowering cholesterol is one of the least important things we can do," he says. "But lowering your triglyceride/HDL ratio will slash your risk of heart disease."
drtommy, using fake credentials really doesn't make anything you say more believable, just the opposite.
Exactly. All the information is available if he wanted to take the time to read it, but that would not fit his agenda.
The other trials were not designed to measure health benefits, just if Vascepa lowered Trigs. Vascepa had two phase III trials and in each met its end points. The FDA then decided that lowering Trigs provided not benefits in preventing CVD by the outcome of two other trials with two different drugs. That was the FDAs scientific evidence to rescind the Anchor label. Just as an example there were 15 failed trials in various statins to prevent CVD. Although they all lowered LDL they did not show any benefit to significantly prevent CVD. The Statins today both lower LDL and prevent CVD significantly so there much exist some other mode of action to help prevent CVD. This is why the FDAs reasoning is flawed. Comparing apples to oranges is not scientific evidence.
Once the date of the 967th event is determined statistician can then determine RRR rate using the placebo rate, total patient hours, patient hours in the control arm, and in the placebo arm. They do not need all the data to determine if, or if not Vascepa is effective they can estimate a range to determine probability of success.
Amarin doesn't need the BBs they are doing fine on their own. Once they shake the leaches like you off they will do quite well. Another day and no interim news and things are beginning to look bad for you.
The 1A victory was for the whole industry and will greatly improve the revenues of their Biopharma stocks holdings which make a large percentage of their portfolios.
I prefer to get my fish oil from China, N. Korea, Iran, and middle eastern countries with toppled regimes. How about the rest of you?
Now you know why The Baker Brothers are invested in Amarin. Just think what 1A rights means to accross the board sales increases for its Biopharma portfolio, Every Pharma stock they owns will produce more revenue. Also, I don't think Amarin will have a problem with introductions for partnerships as a reward by and from the the Baker Bros and the entire biopharma industry.
" We view the AMRN First Amendment win as not only important for AMRN’s ability to fairly promote the off-label benefits of Vascepa, but a win for the entire biopharma industry’s ability to fairly promote
peer reviewed published studies of off-label uses for its products as long as it
follows the key settlement terms that include the following:".
"FDA & the US government agree to be bound by the August 7, 2015 declaration by
the court (click here to view our note on the initial decision) enabling AMRN
to engage in truthful and non-misleading speech promoting the off-label use
of Vascepa in the ANCHOR population that represents 36M patients with
elevated triglycerides (≥200mg/dl to 499mg/dl) vs. on-label promotion for the
3.8M patients represented by the MARINE population (500mg/dl to 2000mg/
dl). In addition, AMRN is able to discuss the cardiovascular benefits seen in
the JELIS populations where EPA (the active ingredient in Vascepa) reduced
major cardiovascular events (MACE) by -19% overall (P=0.011) and -53%
(p=0.043) in a sub group of patients with elevated triglycerides ≥150mg/dl. "
Amarin, in a separate court case, won by its constitutional right to relay truthful information concerning Vascepas off label indications. Amarin was given a temporary injunction while they and the FDA were in settlement negotiation issues concerning constitutional rights to Free Speech. I believe the whole Constitution was itself ratified by the 13 colonies in a time without electronic communications at a faster pace than it did take for the FDA to come to terms with Amarin regarding its Constitutional Right of Free Speech. Since the issues were no more than what the court had ordered the time for settlement would probably still be going on if the court had not lost its patience. Again, stall tactics. In all of the issues between the FDA and Amarin there has been only one party that has acted graciously, steadfastly, truthfully, and with a great deal of integrity and unfortunately that party doe not represent the U.S. Government and what it has become, one mired in politics and its agendas, which in this case had nothing to do with the health and safety of the public.
Except for today volume has been somewhat low, however, there were 4 million shares covered during the last two week period disclosed. AFTER hours tonight we will be able to see the short volume for the next period.
Apologies for the delay in getting back to you, however I wanted to provide an answer in the context of information to be discussed during our fourth quarter 2015 conference call. As we did in yesterday’s conference call, we intend to provide regular updates on our REDUCE-IT progress. As discussed, the process for confirming and formally adjudicating the primary events in REDUCE-IT is both time consuming and difficult to precisely forecast. Following confirmation that the threshold for DMC analysis has been met, we will evaluate the most appropriate disclosure, be that a conference call, conference presentation, webcast or otherwise.
I would ask you what that sounds like to you, but you are in shock and denial mode.,
What is the RRR ( Relative Risk, Reduction) rate for Jan. 9th, assuming 60 day lag time for 967th event, with a 5.0, 5.2, and 5.9 % ( Amarins projected 5.9 % placebo rate based on other trials )
Just A holes like you. You know, the leaches that have been sucking the blood of investors for years. Some, like you, are too stupid to know when their gig is up. By the way, I meant what I said because you are a very, very, very stupid person who NEVER backs up his contention with facts, just bases his opinions on the leach herd movements. You, like many of them, will stay too long and lose most of what you made leaching off of others.